-
Eli Lilly Partners with AmoyDx and Burning Rock for Retevmo Companion Diagnostics
•
The 5th China International Import Expo (CIIE) saw US-based Eli Lilly (NYSE: LLY) announce a partnership with China-based Amoy Diagnostics Co., Ltd (AmoyDx) and Burning Rock Biotech Ltd (NASDAQ: BNR). The collaboration aims to enhance the development of companion diagnostics (CDx) for Retevmo (selpercatinib), the world’s first highly-selective RET kinase…
-
BioNTech’s Comirnaty Gets Limited Authorization in China Amid Scholz Visit
•
Germany-based mRNA specialist BioNTech (NASDAQ: BNTX) reportedly benefited from German Chancellor Olaf Scholz’s visit to China this week. Chinese authorities agreed to a limited authorization for the mRNA-based COVID-19 vaccine Comirnaty (BNT162b2) to be used by German national expatriates living in China, according to media sources including Bloomberg, quoting Scholz.…
-
Organon’s Q3 Results Show Women’s Health Segment Outperforms Amid Global Revenue Decline
•
US-based Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, released its Q3 2022 financial results. Total global revenues were down 4% year-on-year (YOY) in real terms to USD 1.537 billion, but up…
-
Organon Signs MOU with China’s National Health Commission at CIIE
•
Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, announced at the 5th China International Import Expo (CIIE) the signing of a memorandum of understanding (MOU) with the National Health Commission (NHC). The…
-
Ascletis Pharma Presents Phase I Study Results for ASC43F at AASLD
•
China-based Ascletis Pharma Inc. (HKG: 1672) made a poster presentation detailing the abstract of a Phase I study for ASC43F in a single dose to treat non-alcoholic steatohepatitis (NASH) at The Liver Meeting 2022 of the American Association for the Study of Liver Diseases (AASLD). The presentation highlighted the drug’s…
-
Ji Xing Pharmaceuticals’ Omecamtiv Mecarbil Accepted for Review by CDE
•
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that a market filing for its investigational omecamtiv mecarbil has been accepted for review by the Center for Drug Evaluation (CDE). The small molecule is a potential first-in-class cardiac myosin activator being developed as a treatment for heart failure with reduced…
-
Sophway Raises ‘Tens of Millions’ in Angel Round for Endoscope Development
•
Sophway Technology, a full HD endoscope system developer based in Shenzhen, has reportedly raised “tens of millions” of renminbi in an angel financing round. The round was led by Bioching Capital, with contributions from Vinno Capital and TusStar. The proceeds will be used to advance the domestic development of endoscope…
-
CIIE: MET HER2 Precision Diagnosis Alliance Formed to Advance Lung Cancer Treatment
•
The 5th China International Import Expo (CIIE) witnessed the establishment of the MET HER2 precision diagnosis alliance, a collaborative initiative involving AstraZeneca, Daiichi Sankyo, HutchMed, Roche Diagnostics, AmoyDx, LBP Medicine, Deep Informatics, Histo Medical Pathological Diagnosis Center, Rightongene Bio, and Genetron. This alliance aims to enhance the implementation of HER2…
-
CIIE: Bo’ao Lecheng Zone Announces Partnerships with Multinationals
•
The 5th China International Import Expo (CIIE) saw the Bo’ao Lecheng Medical Tourism Pilot Zone management bureau announce a series of strategic partnerships with multinational companies. These collaborations aim to enhance the zone’s capabilities in medical tourism and healthcare innovation. Partnership with Abbott LaboratoriesBoao Yiling and Abbott Laboratories’ diabetes department…
-
Cytiva Announces RMB 60M Investment for China Science Innovation Center at CIIE
•
Cytiva—formerly GE Healthcare Life Sciences and now the life science platform of Danaher Corporation—announced at the 5th China International Import Expo (CIIE) an additional investment of RMB 60 million (USD 8.28 million) to establish a China science innovation center. The entity, valued at RMB 100 million (USD 13.79 million) in…
-
Innovent Biologics’ Tafolecimab Shows Strong LDL-C Reduction in Phase III Study
•
China-based Innovent Biologics, Inc. (HKG: 1801) announced the results of the Phase III CREDIT-1 study for tafolecimab (IBI306), a recombinant fully human anti-PCSK-9 monoclonal antibody (mAb), in Chinese patients with non-familial hypercholesterolemia (non-FH). The findings were presented at the American Heart Association (AHA) Scientific Sessions 2022 as an e-poster (VP173).…
-
Allergan Aesthetics Partners with Sinopharm at CIIE for Aesthetic Medicine
•
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced a partnership with Sinopharm Group Co., Ltd’s global procurement and supply chain service center at the 5th China International Import Expo (CIIE). The collaboration aims to deepen their partnership in several key areas, including product supply security, new product launches, and…
-
Honeywell Partners with Anruite for Smart Manufacturing in China
•
US major Honeywell (NASDAQ: HON) has announced a partnership with China-based Tonghua Anruite Biopharmaceutical Co., Ltd at the 5th China International Import Expo (CIIE). The collaboration aims to delve into smart manufacturing and digital transformation, focusing on building a digital innovation system to enhance the smart upgrade of pharmaceutical industry…
-
Boehringer Ingelheim Launches Rehabilitation Center in Chengdu at CIIE
•
The 5th China International Import Expo (CIIE) saw the unveiling of Boehringer Ingelheim’s Consanas (Chengdu) Rehabilitation Center, a joint effort between the German major and the Chengdu Wenjiang local government. This marks a significant step in enhancing stroke rehabilitation medicine in China. Center ProfileThe Consanas (Chengdu) Rehabilitation Center, focused on…
-
Fosun Pharma Partners with Soong Ching Ling Foundation for Women and Children’s Health
•
The 5th China International Import Expo (CIIE) saw Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announce a partnership with the Shanghai Soong Ching Ling Foundation. The collaboration aims to carry out medical and health public welfare activities for women and children, with Xishuangbanna of Yunnan province as the primary…
-
Jumpcan Partners with Newsoara for PDE4 and Protease Inhibitors in China
•
China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a partnership with compatriot firm Newsoara BioPharma Co., Ltd to develop and commercialize two target products in mainland China. The collaboration involves a PDE4 inhibitor (target product one) and a protease inhibitor (target product two). Jumpcan will pay RMB 180 million (USD 24.8…
-
Novo Nordisk to Invest RMB 400M in Shanghai at CIIE
•
Novo Nordisk (NYSE: NVO) has announced at the 5th China International Import Expo (CIIE) an investment of RMB 400 million (USD 55.2 million) to establish an investment unit in Shanghai. The new unit is designed to maintain ownership of its manufacturing, trade, research and development (R&D), and other business operations…
-
Jiangsu Yahong Initiates Phase III Study for Hexvix in Bladder Cancer Detection
•
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the enrollment of the first subject in a prospective, subject-controlled, multi-center Phase III clinical study. The study aims to assess the additional detection rate and safety of Hexvix, a bladder cancer diagnosis and postoperative detection product,…
-
Betta Pharmaceuticals’ BPI-452080 Accepted for Review by NMPA
•
China’s Betta Pharmaceuticals (SHE: 300558) has announced that a clinical trial filing for its Category 1 drug candidate BPI-452080 has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step forward in the development of the drug, which is designed to treat advanced solid…
